São Paulo - Delayed Quote BRL

Ultragenyx Pharmaceutical Inc. (R2AR34.SA)

Compare

30.57

0.00

(0.00%)

At close: October 22 at 10:43:13 AM GMT-3

No Tool

Measure

UNDO

Redo

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for R2AR34.SA

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ultragenyx Pharmaceutical Inc. (R2AR34.SA)

Comparisons

Indicators

Technicals

Corporate Events

0.00%

0.00%

0.00%

0.00%

35.03%

45.57%

45.57%

Recent News: R2AR34.SA

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

Ultragenyx to Participate in Investor Conferences in December

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit

Ultragenyx Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity?

Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update

Recent 4.1% pullback isn't enough to hurt long-term Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders, they're still up 70% over 1 year